Give me treatment of rheumatoid arthritis
Reading File
Finding Sources
Searching PubMed
"rheumatoid arthritis"[MeSH Terms] AND "treatment"[MeSH Terms]
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information from multiple authoritative textbooks. Let me compile a thorough, well-structured answer.
Treatment of Rheumatoid Arthritis
Based on Firestein & Kelley's Textbook of Rheumatology, Harrison's Principles of Internal Medicine (22nd Ed., 2025), and Goldman-Cecil Medicine.
Core Principle: Treat-to-Target (T2T)
The fundamental paradigm in RA management is treat-to-target - patients should be treated early and aggressively to achieve remission or low disease activity. When RA is treated early, remission is achievable in >50% of patients, with low disease activity in at least another 35%. Disease activity must be regularly measured using validated composite scores (DAS28, CDAI, SDAI, etc.).
Keys to optimizing outcomes:
- Early, accurate diagnosis
- Early DMARD therapy (do not wait)
- Strive for remission in all patients
- Monitor carefully for treatment toxicities
- Treat comorbidities (especially cardiovascular disease, osteoporosis, infection risk)
Three Pillars of Medical Therapy
1. NSAIDs
Used for symptomatic relief only - they do not alter the underlying disease and should never be used without a concurrent DMARD.
- COX-2 selective agents (e.g., celecoxib) cause less GI bleeding but carry cardiovascular risk - use at the lowest effective dose
- Always consider a proton pump inhibitor (PPI) for GI protection
- Monitor for reduced renal blood flow and hypertension
- Non-inferior to naproxen/ibuprofen for cardiovascular outcomes in a major RCT
2. Glucocorticoids
Provide rapid and dramatic symptomatic improvement and reduce radiographic progression, but long-term toxicity limits their use.
- Used as a bridge to DMARD efficacy (DMARDs take 2-6 months to work)
- Risk of serious infection increases by 25% at doses as low as 5 mg/day, and doubles at 5-10 mg/day
- Long-term toxicities: osteoporosis, hyperglycemia, hypertension, cataracts, adrenal suppression
- Use the lowest effective dose for the shortest duration
- Consider prophylaxis for osteoporosis in all patients on long-term steroids
3. DMARDs (the backbone of RA treatment)
All RA patients should receive a DMARD. They are classified into three categories:
A. Conventional (Synthetic) DMARDs (csDMARDs)
These take 2-6 months for maximal effect and require monitoring.
| Drug | Dose | Key Toxicities | Monitoring |
|---|---|---|---|
| Methotrexate (anchor drug) | 10-25 mg/week oral or SQ + folic acid 1 mg/day | Hepatotoxicity, myelosuppression, pneumonitis, teratogen | CBC, LFTs every 2-3 months |
| Hydroxychloroquine | 200-400 mg/day (≤5 mg/kg) | Irreversible retinal damage, cardiotoxicity | OCT + visual fields annually |
| Sulfasalazine | 1000-1500 mg/day (maintenance) | Granulocytopenia, hemolytic anemia (G6PD deficiency) | CBC every 2-4 weeks x 3 months, then every 3 months |
| Leflunomide | 10-20 mg/day | Hepatotoxicity, myelosuppression, teratogen (category X) | CBC, LFTs every 2-3 months |
| Azathioprine | Variable | Myelosuppression | CBC, LFTs |
Methotrexate is the recommended initial anchor DMARD for most patients - it is economical, serious toxicities are rare, and it potentiates the effect of virtually all other DMARDs when used in combination. It is contraindicated in pregnancy.
B. Biologic DMARDs (bDMARDs)
Used when csDMARDs fail or for high disease activity. Always screen for latent TB before starting biologics.
TNF-alpha inhibitors (most commonly used biologics):
- Infliximab (chimeric monoclonal Ab): 3 mg/kg IV at weeks 0, 2, 6, then every 8 weeks (up to 10 mg/kg every 4 weeks)
- Etanercept: 50 mg SQ weekly
- Adalimumab: 40 mg SQ every 2 weeks
- Certolizumab pegol, Golimumab
Toxicities: serious bacterial/fungal infections, reactivation of latent TB, increased lymphoma risk (controversial), demyelinating syndromes, worsening of CHF
Anti-IL-6 receptor agents:
- Tocilizumab and Sarilumab - monoclonal antibodies against the IL-6 receptor
- Effective as monotherapy or combined with methotrexate
- Toxicities: infections, neutropenia, thrombocytopenia, elevated LDL cholesterol, GI perforation risk (avoid in patients with diverticulitis or peptic ulcer history)
Other biologic targets:
- Abatacept (CTLA4-Ig, T-cell co-stimulation inhibitor): 500-1000 mg IV monthly
- Rituximab (anti-CD20, B-cell depletion): 500-1000 mg IV x 2 doses, 2 weeks apart - used in patients who fail anti-TNF
- Anakinra (IL-1 receptor antagonist): less commonly used
C. Targeted Synthetic DMARDs (tsDMARDs) - JAK Inhibitors
Oral agents that inhibit intracellular Janus kinase (JAK) signaling pathways. Advantage over biologics: oral formulation.
| Drug | Selectivity | Dose |
|---|---|---|
| Tofacitinib | JAK1 + JAK3 (minor JAK2) | 5 mg twice daily or 11 mg XR once daily |
| Baricitinib | JAK1 + JAK2 | 2-4 mg once daily |
| Upadacitinib | Selective JAK1 | 15 mg once daily |
Used as monotherapy or combined with methotrexate.
JAK inhibitor safety concerns (important regulatory warnings):
- Increased infections, including herpes zoster (higher risk than other DMARDs)
- Elevated liver transaminases, neutropenia, elevated cholesterol, hypertension
- Tofacitinib specifically: increased risk of thrombosis, major adverse cardiovascular events (MACE), and malignancies vs. TNF inhibitors - risk highest in the elderly
- Monitor LFTs, creatinine kinase, creatinine; caution in patients with history of or risk for thrombosis
Treatment Algorithm / Escalation Strategy
Step 1: Early diagnosis → Start csDMARD (Methotrexate first-line) + bridge with low-dose glucocorticoids
↓ (if inadequate response after 3-6 months)
Step 2: Add second csDMARD (hydroxychloroquine, sulfasalazine) or switch to:
↓
Step 3: Add biologic DMARD (TNF inhibitor preferred first biologic) or JAK inhibitor
↓ (if anti-TNF fails)
Step 4: Switch to different biologic class (rituximab, abatacept, tocilizumab/sarilumab)
Therapy should be escalated rapidly to ensure maximal disease suppression while minimizing toxicity. Combinations of conventional and biologic DMARDs are often necessary for optimal control.
Non-Pharmacological Treatment
- Physical therapy: range-of-motion exercises, joint protection techniques
- Occupational therapy: assistive devices, splinting
- Warmth and activity help relieve stiffness
- Patient education and self-management
Surgical Treatment
For patients with severe joint damage unresponsive to medical therapy:
- Synovectomy
- Tendon repair/reconstruction
- Arthroplasty (joint replacement) - especially hip and knee
- Arthrodesis (joint fusion) for small joints of the hand/wrist
Treatment of Extraarticular Manifestations
Treating the underlying RA generally improves extraarticular features. RA-ILD (interstitial lung disease) is particularly challenging because some DMARDs (methotrexate, leflunomide) also cause pulmonary toxicity - typically managed with high-dose corticosteroids plus immunosuppressants.
Sources: Goldman-Cecil Medicine, p. 2794-2798 | Harrison's Principles of Internal Medicine 22E (2025), p. 2893-2895 | Firestein & Kelley's Textbook of Rheumatology
This is a shared conversation. Sign in to Orris to start your own chat.